Skip to main content
. 2022 Mar 3;6(5):1525–1535. doi: 10.1182/bloodadvances.2021004319

Table 4.

Models’ NRM discrimination by the AUC (95% CI)

SCI HCT-CI Comorbidity-Age[40]* Index Comorbidity-Age[6o]* Index
MSKCC cohort
 Years
  1 70.3 (64.4-76.1) 61.7 (54.6-67.1) 61.0 (54.0-68.1) 58.8 (55.1-67.0)
  2 68.9 (63.3-74.4) 63.1 (55.8-67.2) 62.5 (55.8-69.2) 59.4 (56.9-68.1)
  3 68.7 (63.1-74.4) 63.0 (55.6-66.9) 62.7 (55. 8-69.6) 59.6 (56.9-68.5)
  4 67.5 (61.6-73.5) 63.3 (56.0-67.4) 62.5 (55.4-69.7) 59.9 (56.5-68.6)
Sheba cohort
 Years
  1 72.0 (62.0-76.5) 65.7 (56.7-74.6) 63.7 (55.2-72.2) 64.4 (56.0-72.8)
  2 67.6 (57.4-77.9) 62.8 (53.3-72.2) 61.1 (52.0-70.3) 57.1 (52.4-70.6)
  3 64.9 (54.1-75.7) 63.6 (53.1-74.1) 63.5 (53.0-74.1) 62.4 (51.9-73.0)
  4 61.8 (48.0-75.5) 64.4 (52.7-76.1) 61.9 (49.8-74.0) 59.2 (46.6-71.8)
*

The Comorbidity-Age Index was developed with age ≥ 40 years as a threshold to add a point to the HCT-CI. Because the impact of age has likely changed over time, we tested the index with the original age threshold (Comorbidity-Age[40] Index) and with age ≥ 60 years as a threshold (Comorbidity-Age[60] Index).